The clonal diversity of peripheral b cell receptor immune repertoire impaired by residual malignant b cells predicts treatment efficacy in b cell lymphoma patients

HIGHLIGHTS

• who: Meng Wu and colleagues from the Department of Lymphoma, Peking University Cancer Hospital and Institute, China have published the research work: The Clonal Diversity of Peripheral B Cell Receptor Immune Repertoire Impaired by Residual Malignant B Cells Predicts Treatment Efficacy in B Cell Lymphoma Patients, in the Journal: Cancers 2022, 14, 4628. of 23/09/2022
• how: The results showed that the presence of residual DLBCL cells could significantly impair the normal physiological diversification of repertoire B cells. FCM was carried out on a NovoSampler Pro or a NovoSampler Q (NovoCyte Surrey UK) system . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.